Medical instrumentation company, Diopsys, has developed an office-based NOVA-Pattern electroretinography (PERG) vision test for use in hospitals and research facilities by optometrists and ophthalmologists.
By utilising visual evoked potential technology, NOVA-PERG measures the function of the inner retinal cells of the eye, with a focus on the macula.
Patients view a screen with alternating checkerboard patterns to elicit a PERG response, according to the company.
The information provided by the test helps optometrists and ophthalmologists diagnose and monitor vision disorders like glaucoma, macular degeneration and diabetic retinopathy.
Diopsys research director Dr Alberto Gonzalez said the test is an important addition to the company's suite of diagnostic tools for eye care professionals.
"In one sitting, an eye care specialist can objectively measure the function of the patient's retina while also measuring the function of the entire vision system, from the eye to the visual cortex," Gonzalez said.
"This will help doctors objectively distinguish between retinal and cortical pathway issues."
In addition to vision testing devices, Diopsys is involved in delivering preventative healthcare solutions to optometrists and ophthalmologists.
The company said it is planning to launch its NOVA-PERG vision test in late 2012.